PDS Biotechnology (PDSB) announced that the U.S. Patent Office has issued a Notice of Allowance for the Company’s lead asset, PDS0101. “This patent reinforces the value of our proprietary Versamune platform and our lead asset PDS0101 as we advance through late-stage development,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. “With VERSATILE-003 progressing and a robust intellectual property portfolio now extending across multiple major markets, we are well-positioned to bring this promising immunotherapy to patients with head and neck cancers.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- PDS Biotechnology Updates Phase 3 Trial Design for PDS0101
- PDS Biotechnology announces FDA alignment on use of PFS as primary endpoint
- PDS Biotechnology Secures New Patent for PDS0101
- PDS announces new composition of matter patent for PDS0101 in Japan
- PDS Biotechnology Gains FDA Meeting for PDS0101 Approval